
Pasirinkite etiketę
rodoma tiesiai ant flakonoLaboratorijos ataskaitų: 7
PDF- Ištirta
- Retatrutide 10mg
- Laboratorija
- Analiza Białek
- Data
- November 2026
- Rezultatas
- 99% purity (10.37 mg measured)
- Endotoksinai
- 5.54 EU/vial
- Užsakymo nr.
- Slaptažodis
PDF- Ištirta
- Retatrutide 15mg
- Laboratorija
- Analiza Białek
- Data
- November 2026
- Rezultatas
- 99% purity (16.53 mg measured)
- Endotoksinai
- 5.91 EU/vial
- Užsakymo nr.
- Slaptažodis
PDF- Ištirta
- Retatrutide 30mg
- Laboratorija
- Analiza Białek
- Data
- November 2026
- Rezultatas
- 99% purity (31.88 mg measured)
- Endotoksinai
- 6.29 EU/vial
- Užsakymo nr.
- Slaptažodis
PDF- Ištirta
- Retatrutide 40mg
- Laboratorija
- Analiza Białek
- Data
- November 2026
- Rezultatas
- 99% purity (40.92 mg measured)
- Endotoksinai
- 6.82 EU/vial
- Užsakymo nr.
- Slaptažodis
PDF- Ištirta
- Retatrutide 60mg
- Laboratorija
- Analiza Białek
- Data
- November 2026
- Rezultatas
- 99% purity (60.10 mg measured)
- Endotoksinai
- 7.73 EU/vial
- Užsakymo nr.
- Slaptažodis
PDF- Ištirta
- Retatrutide 20mg
- Laboratorija
- Analiza Białek
- Data
- October 2026
- Rezultatas
- 99% purity (23.28 mg measured)
- Endotoksinai
- 6.15 EU/vial
- Užsakymo nr.
- Slaptažodis
PDF- Ištirta
- Retatrutide 5mg
- Laboratorija
- Analiza Białek
- Data
- July 2026
- Rezultatas
- 99% purity (5.28 mg measured)
- Užsakymo nr.
- Slaptažodis
Ištirta nepriklausomai, su slaptažodžiu galima patikrinti tiesiogiai laboratorijoje.
Retatrutide
GLP-1
- Patikrinta laboratorijoje · 99% grynumas
- Siunčiame iš Vokietijos
Užsakymas
- DHL su sekimu
- Diskreti pakuotė
4.6 iš 5 TrustpilotAtsiliepimų: 73
Taip pat ieškoma kaip: Retatrutid · Reta · LY3437943
Trumpai
Retatrutide skaičiais
Pagrindiniai rodikliai iš mūsų žinyno. Vilkite tašką kreive, kad pamatytumėte, kiek lieka po vienos dozės, pagal skaičiavimą.
Visas žinyno įrašasHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~6 days
Simplified model without an absorption phase, half-life from the TPD lexicon.
Half-life
~6days
- Class
- Triple agonistGLP-1 / GIP / glucagon
- Frequency
- Once weeklysubcutaneous
- Form
- Lyophilised powderreconstituted with BAC water
- Sizes
- 5 to 60 mg11 sizes in the shop
What studies show
All 10 sources in the lexicon- up to25 %
Phase 3 trial TRIUMPH-1 in obesity (up to 25% weight reduction at 80 weeks) (opens in a new tab)
Jastreboff et al., New England Journal of Medicine, 2026 - up to18.8 %Bellido et al., The Lancet, 2026
- up to~24 %
Phase 2 study in obesity (up to ~24% weight reduction at 48 weeks) (opens in a new tab)
Jastreboff et al., New England Journal of Medicine, 2023
Žinios
Viskas apie Retatrutide
Išsami informacija netrukus.
Dozavimas
Įkeliama dozavimo informacija …
Pravers
Ko dar jums reikės
Bakteriostatinis vanduo į krepšelį pridedamas automatiškai. Švirkštai ir servetėlės - vienu paspaudimu.
Insulino švirkštai
10 vnt. · 5.50 €
Spiritinės servetėlės
50 vnt. · 10 €
Kiek vandens?
Vienetai ant švirkšto jūsų flakono dydžiui.
Atidaryti skaičiuoklę →Is Retatrutide approved?
No, as of 25 October 2026 there is no approval. Retatrutide is in phase 3: 14 phase 3 trials are listed on ClinicalTrials.gov, five of them completed. The first phase 3 results were published in 2026.
How does Retatrutide differ from Tirzepatide and Semaglutide?
The number of receptors. Semaglutide acts only on the GLP-1 receptor, Tirzepatide on GLP-1 and GIP. Retatrutide also targets the glucagon receptor. In animal models this added higher energy expenditure. A head-to-head trial against Tirzepatide is still running (TRIUMPH-5).
What did the phase 3 trials show?
In TRIUMPH-1 (obesity without diabetes) weight fell by 25.0 percent on average after 80 weeks at the highest study dose, by 3.9 percent on placebo. In TRIUMPH-2 (with type 2 diabetes) it was 18.8 versus 5.1 percent. In TRANSCEND-T2D-1 long-term blood sugar (HbA1c) fell by up to 1.94 percentage points in 40 weeks.
What happens to liver fat?
In a substudy with fatty liver (MASLD) liver fat fell by about 81 to 82 percent after 24 weeks in the two higher levels. 86 percent reached normal liver fat below 5 percent at the highest level. A large phase 3 trial on liver disease runs until 2030.
Which side effects were seen?
Most often gastrointestinal effects such as nausea and diarrhoea, depending on the dose. In TRIUMPH-2 abnormal skin sensations (dysaesthesia) and low blood pressure occurred more often than on placebo. In the phase 2 trial heart rate rose in a dose-dependent way, most around week 24.
Which trials are still running?
Nine phase 3 trials are not finished yet. The largest: TRIUMPH-OUTCOMES on heart and kidney events with about 10,000 participants (planned end 2029) and SYNERGY-Outcomes on fatty liver (2030). The comparison with Tirzepatide (TRIUMPH-5) is due to reach its primary endpoint in November 2026.
Palyginimai
Kuo skiriasi
Susiję
Susiję produktai
Tirzepatide
Peptidai · GLP-1 ir riebalų mažinimas GLP-1 ir riebalų mažinimas
Dydžių: 10
Patikrinta laboratorijoje
= nuo 10 €/flakonas
Semaglutide
Peptidai · GLP-1 ir riebalų mažinimas GLP-1 ir riebalų mažinimas
Dydžių: 6
Patikrinta laboratorijoje
= nuo 10 €/flakonas
Mazdutide
Peptidai · GLP-1 ir riebalų mažinimas GLP-1 ir riebalų mažinimas
Dydžių: 2
= nuo 32 €/flakonas
Survodutide
Peptidai · GLP-1 ir riebalų mažinimas GLP-1 ir riebalų mažinimas
1 dydis
= 60.8 €/flakonas
Retatrutide

